Transverse Myelitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years of age or older when you sign up for the registry.
- You must have a confirmed diagnosis of a specific type of neuromyelitis optica spectrum disorder (a rare condition affecting the spinal cord and optic nerves), confirmed by a positive AQP4 antibody test (confirm with trial site).
- You must currently be taking a specific medication (either eculizumab or ravulizumab) to help prevent relapses of your condition, and must have received a recent dose within a specific timeframe before joining.
- Your medical records must include details of your dosing history since you started the medication, as well as information about any relapses you had in the year before you started taking it up until the time you join the registry.
Who may not be able to join:
- You may not be able to join if you are currently taking part in another clinical trial that involves a drug treatment for the same condition.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pablo Lopez, Hospital Aleman
Phone: 1-855-752-2356
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Annualized Relapse Rate (ARR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.